Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Completes Merger, Raises $88.2M in Stock Offering

NEW YORK, Feb. 9 (GenomeWeb News) - Genome Therapeutics has completed its merger with Genesoft Pharmaceuticals and its common stock offering, the company said on Friday.


The common stock offering raised gross proceeds of approximately $88.2 million, the Waltham, Mass.-based company said. Genome Therapeutics sold $16.8 million shares at $5.25 per share.


As a result of the merger and the financing, Genome Therapeutics has about $110 million in cash and cash equivalents.


The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.